演題詳細

一般口演 / Oral Session

一般口演 3 (Oral Session 3) :AML:再発・難治性AML

print

日程
2013年10月11日(金)
時間
09:30 - 10:30
会場
第4会場 / Room No.4 (さっぽろ芸文館 3F 黎明)
座長・司会
市川 幹 (Motoshi Ichikawa):1
1:湘南東部総合病院・クリニック 血液・腫瘍内科
 
前へ戻る

Cytogenetic clonal evolution patterns in relapsed AML following allogeneic HSCT

演題番号 : OS-1-13

湯淺 光博 (Mitsuhiro Yuasa):1、内田 直之 (Naoyuki Uchida):1、梶 大介 (Daisuke Kaji):1、太田 光 (Hikaru Ota):1,2、西田 彩 (Aya Nishida):3、石綿 一哉 (Kazuya Ishiwata):1、荒岡 秀樹 (Shinsuke Takagi):4、辻 正徳 (Masanori Tsuji):1、高木 伸介 (Shinsuke Takagi):3、山本 久史 (Hisashi Yamamoto):1、森 有紀 (Yuki Mori):1、山本 豪 (Go Yamamoto):1、増岡 和宏 (Kazuhiro Masuoka):5、和氣 敦 (Atsushi Wake):3、伊豆津 宏二 (Koji Izutsu):1、牧野 茂義 (Shigeyoshi Makino):2、米山 彰子 (Akiko Yoneyama):3、谷口 修一 (Shuichi Taniguchi):1

1:Department of Hematology, Toranomon Hospital, Minato-Ku, Tokyo, Japan.、2:Department of Transfusion Medicine, Toranomon Hospital, Minato-Ku, Tokyo, Japan、3:Dept. of Hematology, Toranomon Hospital Kajigaya, Japan、4:Department of Infectious Diseases, Toranomon Hospital, Minato-Ku, Tokyo, Japan、5:Dept. of Hematology, Mishuku Hospital, Meguro, Japan

 

[Introduction] Relapse of AML has been associated with cytogenetic clonal evolution in 40% of patients who have received chemotherapy. But little is known about relapse after allo-HSCT. [Methods] We retrospectively reviewed patients diagnosed as AML who underwent first allo-HSCT at our institute from 2007 to 2012 and analysed the cytogenetic evolution patterns in patient at relapse of AML after HSCT. [Results] 330 patients were included in this study. We identified 56 (17%) relapsed in the bone marrow after HSCT, comparing karyotypes before and after transplantation. Median age at HSCT was 56 years (21-82) and 8 (14%) are still alive. 6 (11%) had normal karyotype before HSCT. 19 (34%) had one chromosome abnormality. 9 (16%) had two abnormalities. Median observation time after HSCT was 16 months (1-75). 16 (29%) did not change any karyotype between HSCT (group1). 14 (25%) had the same karyotype but also other karyotypes (group2). 18 (32%) had the similar karyotype, which was loss or gain of chromosomal abnormalities from original one (group3). 7 (13%) had totally different karyotype (group4). Median onset-time of relapse after HSCT of each group is 6 months (2-24), 3 (1-73), 5 (2-24), 7(1-26), respectively. Median survival time after HSCT is 20 months (2-36), 7 (1-75), 10 (3-45), 25 (1-45), respectively.[Conclusion] Although durations from HSCT to relapse were comparable among 4 groups, median survival time after HSCT tended to be shorter in those in group 2 and 3, suggesting cytogenetic clonal evolution (group 2 and 3) may confer resistant characters against treatments.

前へ戻る